It is made available under a CC-BY 4.0 International license.

2 **variables and serum protein biomarkers**

- 3
- 4 Louise C. LAURENT, MD, PhD^{1*}, George R. SAADE, MD², Glenn R. MARKENSON, MD³, Kent D. HEYBORNE,
- 5 MD⁴, Corina N. SCHOEN, MD⁵, Jason K. BAXTER, MD⁶, Sherri A. LONGO, MD⁷, Leonardo M. PEREIRA,
- 6 MD⁸, Emily J. SU, MD⁹, Matthew K. HOFFMAN, MD¹⁰, Garrett K. LAM, MD¹¹, Angela C. FOX, MS¹², Ashoka
- D. POLPITIYA, D Sc¹², Md. Bahadur BADSHA, PhD¹², Tracey C. FLEISCHER, PhD¹², Thomas J. GARITE, MD¹²,
- 8 J. Jay BONIFACE, PhD¹², Paul E. KEARNEY, PhD¹²
- 9
- 10 ¹Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego,
- 11 La Jolla, CA
- ² Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA
- ³ Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA
- 14 ⁴ Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO, and
- 15 Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, CO
- ⁵ 16 Department of Obstetrics and Gynecology, University of Massachusetts-Baystate, Springfield, MA
- 17 ⁶ Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson
- 18 University, Philadelphia, PA
- 19 ⁷ Department of Obstetrics and Gynecology, Ochsner Health, New Orleans, LA
- 8 20 ⁸ Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR
- ⁹ Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO
- ¹⁰ Department of Obstetrics and Gynecology, ChristianaCare Health System, Wilmington DE
- 23 ¹¹ Regional Obstetrical Consultants, Chattanooga, TN; Department of Obstetrics & Gynecology,
- 24 University of Tennessee Health Science Center and College of Medicine, Chattanooga, TN

It is made available under a CC-BY 4.0 International license.

- 25 Sera Prognostics, Inc., Salt Lake City, UT
-
- ***Corresponding Author**
- Louise C. LAURENT, MD, PhD
- Professor
- Co-Chair, Center for OB/GYN Research Innovation
- Department of Obstetrics, Gynecology, and Reproductive Sciences
- Division of Maternal Fetal Medicine
- The Sanford Consortium for Regenerative Medicine
- University of California, San Diego
- 2880 Torrey Pines Scenic Dr.
- La Jolla, CA 92037-0695
- Phone: 858-246-1405
- FAX: 858-534-8329
- llaurent@ucsd.edu
-

Financial support

- Financial support for the study was provided by Sera Prognostics, Inc. The sponsor funded the study,
- generated biomarker data and discovered and blindly validated the predictors.
-
- **Short title**
- Proteomic biomarker risk predictors for preterm preeclampsia
-
- **Acknowledgments**

It is made available under a CC-BY 4.0 International license.

Manuscript word count: 3372

It is made available under a CC-BY 4.0 International license.

Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical

- **variables and serum protein biomarkers**
-

Précis

- Combining novel serum protein biomarkers and selected clinical variables for preterm preeclampsia
- prediction outperforms widely used clinical risk assessment algorithms currently recommended by
- practice guidelines.
-
- **Abstract**
- *Objective*
- To develop and validate mid-trimester preterm preeclampsia (PE) risk predictors combining clinical

factors and serum protein analytes, and to compare their performance with those of widely used clinical

and risk assessment algorithms endorsed by professional societies.

Methods

 This was a secondary analysis of data from two large, multicenter studies in pregnant individuals (PAPR, NCT01371019; TREETOP, NCT02787213), originally conducted to discover, verify, and validate a serum proteomic predictor of preterm birth risk. Serum protein abundances were determined by mass spectrometry. Classifier models combined one or two novel protein ratio(s) with a composite clinical variable, denoted as ClinRisk3, which included prior PE, pre-existing hypertension, or pregestational diabetes. Predictive performance was assessed for the full validation cohort and for a subset that had early gestational age (GA) dating via ultrasound. Classifier performance was compared directly to the U.S. Preventive Services Task Force (USPSTF) algorithm for identification of pregnancies that should receive low-dose aspirin (LDASA) for PE prevention.

It is made available under a CC-BY 4.0 International license.

- *Results*
- Nine of nine prespecified classifier models were validated for risk of preterm PE with delivery <37
- weeks' gestation. Areas under the receiver operating characteristic curve ranged from 0.72-0.78 in the
- full validation cohort, compared to 0.68 for both ClinRisk3 alone and for the USPSTF algorithm. In the
- early GA dating subcohort, an exemplar predictor, ClinRisk3 + inhibin subunit beta C chain/sex hormone
- binding globulin (ClinRisk3+INHBC/SHBG) showed a markedly lower screen positive rate (11.1% vs
- 43.3%) and higher positive predictive value (13.0% vs 5.0%) and odds ratio (9.93 vs 5.24) than USPSTF.
- 102 Its performance was similar in nulliparas and all parities.
-
- *Conclusion*
- Nine preterm PE risk predictors were identified, validated in an independent cohort, and shown to be
- more predictive than the USPSTF-endorsed algorithm. Our results indicate that a single blood test
- performed in the first half of pregnancy can be used for personalized PE risk assessment, particularly for
- pregnancies with minimal or no identified clinical risk factors, including nulliparas. Results can be used to
- guide personalized pregnancy management, including but not restricted to LDASA for PE prophylaxis,
- 110 and serve as a basis for developing new prevention strategies.
-
- *Funding Source*
- 113 Sera Prognostics, Inc.

It is made available under a CC-BY 4.0 International license.

Introduction

It is made available under a CC-BY 4.0 International license.

138 heterogeneous,^{18,19} biomarker studies should at minimum assess performance for early-onset and late-139 onset cases separately. $8,20,21$

 There is an urgent need for an accurate, safe, and practical predictor for preterm PE, particularly for nulliparas. A predictor with good AUC (>0.70), sensitivity (>50%), and PPV (>5%) at a reasonably low screen positive rate (SPR) (<15%) would markedly improve identification of high-risk pregnancies for LDASA prophylaxis, increased surveillance, and research studies compared to current clinical paradigms, while a high negative predictive value (NPV; >99%) would enable low-risk patients to safely forgo or discontinue unnecessary interventions. This study aimed to develop and validate a mid-trimester predictor comprising molecular biomarkers and relevant clinical factors across demographically, geographically, and temporally diverse populations, comparing predictive performance to that of currently used risk assessment paradigms. **Methods** 151 Biomarker development was based on U.S. National Academy of Medicine guidelines.²² This was a secondary analysis, using data from two large, multicenter U.S. cohort studies, conducted to discover, verify, and validate risk predictors for preterm PE. The Proteomic Assessment of Preterm Risk (PAPR, 154 NCT01371019)²³ and the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

155 (TREETOP, NCT02787213)²⁴ studies were prospective, observational studies conducted to develop a

maternal serum-based proteomic biomarker for PTB risk stratification. Study approvals were provided

by site IRBs, and participants provided written informed consent.

158 PAPR and TREETOP enrolled gravidas ≥18 years of age with singleton pregnancies from 17^{0/7}-159 $28^{6/7}$ or $17^{0/7}$ -21^{6/7} weeks' gestation, respectively, and excluded pregnancies with planned delivery <37^{0/7} weeks' gestation, major anomalies or chromosomal disorders, or planned cervical cerclage. GA was

161 determined according to ACOG criteria^{25,26}. In TREETOP, progesterone use after $13^{6/7}$ weeks' gestation

It is made available under a CC-BY 4.0 International license.

 was an exclusion criterion. Demographic, medical and pregnancy history, medication, and post-delivery maternal and infant outcome information was collected. No attempt was made to control for LDASA use in these studies. Adjudication of PE and PTB cases was blinded, occurring prior to database lockdown and analyses.

 Discovery was performed in a PAPR-derived cohort that was distinct from the TREETOP-derived verification and validation cohorts (**Fig. 1**). The discovery and verification/validation cohorts included 168 blood samples drawn $18^{0/7}$ -22^{6/7} and $18^{0/7}$ -20^{6/7} weeks' gestation, respectively. The discovery cohort used a broader GA at blood draw (GABD) window to increase sample size. TREETOP subjects enrolled before April 18, 2018 were randomly assigned by an independent third-party statistician to blinded 171 verification (one-third) or validation (two-thirds) cohorts.²⁴ The validation cohort also included six months of later enrollment at four additional sites not represented in the verification cohort. Cases were defined as subjects with PE who delivered <37 weeks' gestation, and controls were defined as noncases,

inclusive of term PE and sPTB.

175 Maternal blood was collected, processed and stored as described previously.^{23,24} Serum samples

were depleted of abundant proteins, reduced, alkylated, and digested with trypsin. Stable isotope

standard (SIS) peptides were added post-digest, and peptides were analyzed by a liquid

178 chromatography-multiple reaction monitoring mass spectrometry assay.^{23,27} Quantification was based

on peptide response ratios, wherein the area of each endogenous peptide was divided by that of its

corresponding SIS. Sample batches were required to meet quality control metrics.

 Biomarker measurements were made for 77 proteins, comprising those enriched for pathways relevant to pregnancy conditions and quality control proteins. Proteins for building classifier models were prefiltered using analytical performance criteria, including mass spectrometry peak area cutoffs, coefficients of variance from replicate quality control samples, and preanalytic stability. Simple models were then constructed to avoid overfitting and to leverage protein ratios for normalizing and amplifying

It is made available under a CC-BY 4.0 International license.

- 186 predictive signals²³. Models included one novel two-protein ratio and a composite clinical variable.
- Based on strong predictive performance in nulliparous individuals, the log ratio of insulin-like growth
- factor-binding protein 4 (IBP4) to sex hormone-binding globulin (SHBG) was included in models as a
- second two-protein ratio unless SHBG was part of the novel ratio. Among many clinical factors specified
- 190 in current practice guidelines,^{7,28-32} three (PE in a previous pregnancy, pre-existing hypertension, and
- pregestational diabetes) were selected and combined into one variable (ClinRisk3), which was deemed
- positive if any was true for the subject. This simple, fixed approach reduced overfitting, leveraged prior
- biomarker knowledge, and produced classifiers that followed two model structures:
-
- 194 $1. \quad A_1^*$ log(IBP4/SHBG) + A_2^* ClinRisk3 + A3*log(X/Y) or
-

195 2. A_1^* ClinRisk3 + A_2^* log (X/SHBG)

 where X and Y are protein analytes, identified herein by Uniprot name without species identifier. Model coefficients Ai were fit using logistic regression.

 In discovery, models were ranked by a combination of area under the receiver operating characteristic curve (AUC) and correlation with GAD amongst preeclamptic subjects. Candidate models ascertained in discovery were confirmed and tuned in verification to account for temporal changes in care and population, then validated by an independent third-party statistician. Each classifier was initially validated using AUC, then *P*-value, for three score thresholds distinguishing higher from lower risk. Thresholds were predefined based on discovery performance to allow for sensitivity and specificity tradeoffs and to enable use in varied clinical settings.

 Previously we showed that for prediction of spontaneous PTB using protein biomarkers, better 206 estimation of test performance is obtained in more precisely GA-dated individuals.³³ Since crown-rump 207 length is more precise when determined prior to $9^{0/7}$ weeks' gestation,²⁶ post-validation performance 208 metrics were calculated on a sub-cohort comprised of subjects dated by ultrasound prior to $9^{0/7}$ -weeks' gestation (early GA dating). Performance metrics were calculated for GA cutoffs of <37 and <34 weeks in

It is made available under a CC-BY 4.0 International license.

 all subjects and in nulliparous individuals. PE prevalence was calculated on the TREETOP validation cohort and was consistent with the broader U.S. population, as represented by National Vital Statistics 212 System (NVSS) reporting³⁴ and Lisonkova et al. $(2013)^8$ (e.g., for PE <34 weeks: TREETOP, 1.13%; Lisonkova, 1.24%; *P*=0.78). 214 Guidelines³⁵ set by the U.S. Preventive Services Task Force (USPSTF) for PE clinical risk factor assessment were compared to the biomarker-driven model. The TREETOP validation dataset contained most USPSTF-prescribed clinical risk factors, including prior history of preeclampsia, chronic hypertension, type 1 or type 2 diabetes, kidney disease, multi-gestational birth, elevated pre-pregnancy body mass index, instances of nulliparous births, and maternal African American heritage (attributed to socioeconomic factors). Using these variables, a classifier was developed to approximate the USPSTF risk assessment and compare its performance with biomarker-driven models using the same predefined benchmarks. Analyses were conducted according to prespecified protocols. Laboratory personnel and statisticians were blinded to clinical data. Data linked to classifier scores were analyzed by an independent third-party statistician. Type I error was controlled by fixed sequence hypothesis 225 testing.^{36,37} The sample size of the validation sub-cohort was shown to have 84% power at 5% alpha to detect by Fisher's exact test an enrichment of spontaneous PTB cases above a predictor score threshold

227 associated with two-fold increased risk.³⁸ For the purpose of validating preterm PE classifiers, this sub-

cohort was estimated to show >90% power at 5% alpha to detect by regression test a significant

enrichment above a 75% sensitivity threshold. At such a threshold, the sub-cohort sample size was

estimated to produce a 95% CI width for sensitivity of <25% and for specificity of <5%.

 Unless otherwise specified, all statistical tests were 2-tailed at significance <0.05 and performed 232 in R v3.5.1 or higher.³⁹ Count differences in categorical variables were assessed using the chi-squared 233 test, and median differences in continuous variables were assessed with the Wilcoxon test.⁴⁰

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

 nulliparas (sensitivity 53.3%, PPV of 6.9%, and NPV of 99.8% at a SPR of 11.7%) is superior to standard- of-care clinical risk assessment approaches endorsed by NICE, ACOG, and USPSTF, and also compares favorably with the more burdensome approach endorsed by the FMF, which is comprised of not only clinical factors and a protein biomarker, but also uterine artery Doppler measurement, which is unfeasible for universal screening. ClinRisk3+INHBC/SHBG and the other predictors validated in this study can be used to select high-risk pregnancies for interventional studies of prophylactic or therapeutic agents. Determining whether preventive or therapeutic interventions alter biomarker levels in maternal serum is also of interest. Clinical application of a screening test is a two-step process: The first step, reported here, is validation of the biomarkers' predictive abilities. The second, demonstrating clinical utility – i.e., improved outcomes, cost effectiveness, and ease of implementation – requires additional work. Strengths of the study include the large, diverse, and temporally distinct datasets used for discovery, verification, and validation. The composite clinical variable uses readily ascertained factors, and the biomarkers were prefiltered for excellent performance in ambient temperature sample transport conditions. These properties support practicality for clinical use. Limitations include the modest number of early preterm PE cases due to the low prevalence of the condition and a mid-369 trimester blood draw window $(18^{0/7}-22^{6/7})$ weeks' GA) that falls within the guideline-recommended 370 timeframe for LDASA initiation (12-28 week's GA, optimally <16 weeks' GA).⁷ In summary, nine mid-trimester preterm PE risk predictors, designed to assess both proteomic biomarkers and clinical risk factors from 18-20 weeks' gestation, demonstrated predictive ability

 superior to that of clinical factors alone. ClinRisk3+INHBC/SHBG includes biomarkers with functional relevance to pregnancy. All show promise for detecting risk of PE <34 weeks' GA and identifying pre- symptomatic individuals who can benefit from increased surveillance, LDASA prophylaxis, and future therapies.

It is made available under a CC-BY 4.0 International license.

References

- 1. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and
- Perspectives. *Circ Res*. Mar 29 2019;124(7):1094-1112. doi:10.1161/CIRCRESAHA.118.313276
- 2. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal
- death: a WHO systematic analysis. *Lancet Glob Health*. Jun 2014;2(6):e323-33. doi:10.1016/S2214-
- 109X(14)70227-X
- 3. Vogel JP, Souza JP, Mori R, Morisaki N, Lumbiganon P, Laopaiboon M, et al. Maternal
- complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on
- Maternal and Newborn Health. *BJOG*. Mar 2014;121 Suppl 1:76-88. doi:10.1111/1471-0528.12633
- 4. Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of the
- problem. *Clin Perinatol*. Mar 2008;35(1):53-67, viii. doi:10.1016/j.clp.2007.11.001
- 5. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent
- Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for
- the US Preventive Services Task Force. *JAMA*. Sep 28 2021;326(12):1192-1206.
- doi:10.1001/jama.2021.8551
- 6. Chronic Hypertension in Pregnancy. ACOG Practice Bulletin No. 203. American College of
- Obstetricians and Gynecologists. *Obstet Gynecol*. Jan 2019;133(1)e26-
- e50.doi:10.1097/AOG.0000000000003020
- 7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. American
- College of Obstetricians and Gynecologists. *Obstet Gynecol*. Jun 2020;135(6)e237-
- e260.doi:10.1097/AOG.0000000000003891
- 8. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with
- early- versus late-onset disease. *Am J Obstet Gynecol*. Dec 2013;209(6):544 e1-544 e12.
- doi:10.1016/j.ajog.2013.08.019

It is made available under a CC-BY 4.0 International license.

- 9. Hao J, Hassen D, Hao Q, Graham J, Paglia MJ, Brown J, et al. Maternal and Infant Health Care
- Costs Related to Preeclampsia. *Obstet Gynecol*. Dec 2019;134(6):1227-1233.
- doi:10.1097/AOG.0000000000003581
- 10. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. *Mol*
- *Aspects Med*. Apr 2007;28(2):227-44. doi:10.1016/j.mam.2007.04.002
- 11. Bahado-Singh RO, Syngelaki A, Akolekar R, Mandal R, Bjondahl TC, Han B, et al. Validation of
- metabolomic models for prediction of early-onset preeclampsia. *Am J Obstet Gynecol*. Oct
- 2015;213(4):530 e1-530 e10. doi:10.1016/j.ajog.2015.06.044
- 12. Koster MP, Vreeken RJ, Harms AC, Dane AD, Kuc S, Schielen PC, et al. First-Trimester Serum
- Acylcarnitine Levels to Predict Preeclampsia: A Metabolomics Approach. *Dis Markers*.
- 2015;2015:857108. doi:10.1155/2015/857108
- 13. Srinivasan S, Treacy R, Herrero T, Olsen R, Leonardo TR, Zhang X, et al. Discovery and
- Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in
- Asymptomatic Women. *Cell Rep Med*. May 19 2020;1(2)doi:10.1016/j.xcrm.2020.100013
- 14. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the
- sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. Jan 7 2016;374(1):13-22.
- doi:10.1056/NEJMoa1414838
- 15. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing
- to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-
- randomised controlled trial. *Lancet*. May 4 2019;393(10183):1807-1818. doi:10.1016/S0140-

6736(18)33212-4

- 16. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, et al. First
- trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history

It is made available under a CC-BY 4.0 International license.

- for the prediction of preeclampsia. *Placenta*. Jun 2012;33(6):495-501.
- doi:10.1016/j.placenta.2012.03.003
- 17. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and
- small for gestational age at 11-13 weeks. *Fetal Diagn Ther*. 2013;33(1):16-27. doi:10.1159/000341712
- 18. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised Placental
- Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. *Hypertension*.
- Jul 2016;68(1):137-47. doi:10.1161/HYPERTENSIONAHA.116.07293
- 19. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global Pregnancy C. Subtypes of
- Preeclampsia: Recognition and Determining Clinical Usefulness. *Hypertension*. May 5 2021;77(5):1430-
- 1441. doi:10.1161/HYPERTENSIONAHA.120.14781
- 20. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology
- of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to
- late-onset preeclampsia. *Am J Obstet Gynecol*. Feb 2022;226(2S):S867-S875.
- doi:10.1016/j.ajog.2021.11.019
- 21. Masini G, Foo LF, Tay J, Wilkinson IB, Valensise H, Gyselaers W, Lees CC. Preeclampsia has two
- phenotypes which require different treatment strategies. *Am J Obstet Gynecol*. Feb 2022;226(2S):S1006-
- S1018. doi:10.1016/j.ajog.2020.10.052
- 22. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical
- Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine. In: Micheel
- CM, Nass SJ, Omenn GS, eds. *Evolution of Translational Omics: Lessons Learned and the Path Forward*.
- National Academies Press (US)
- Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012.

It is made available under a CC-BY 4.0 International license.

- 23. Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, et al. Development and
- validation of a spontaneous preterm delivery predictor in asymptomatic women. *Am J Obstet Gynecol*.
- May 2016;214(5):633 e1-633 e24. doi:10.1016/j.ajog.2016.02.001
- 24. Markenson GR, Saade GR, Laurent LC, Heyborne KD, Coonrod DV, Schoen CN, et al. Performance
- of a proteomic preterm delivery predictor in a large independent prospective cohort. *Am J Obstet*
- *Gynecol MFM*. Aug 2020;2(3):100140. doi:10.1016/j.ajogmf.2020.100140
- 25. American College of Obstetricians and Gynecologists. Committee opinion no 611: method for
- estimating due date. *Obstet Gynecol*. Oct 2014;124(4):863-866.
- doi:10.1097/01.AOG.0000454932.15177.be
- 26. Methods for Estimating the Due Date. Committee Opinion No 700 American College of
- Obstetricians and Gynecologists. *Obstet Gynecol*. May 2017;129(5)e150-
- e154.doi:10.1097/AOG.0000000000002046
- 27. Bradford C, Severinsen R, Pugmire T, Rasmussen M, Stoddard K, Uemura Y, et al. Analytical
- validation of protein biomarkers for risk of spontaneous preterm birth. *Clinical Mass Spectrometry*.
- 2017/01/01/ 2017;3:25-38. doi:10.1016/j.clinms.2017.06.002
- 28. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis
- and management (NICE Guideline, NG 133). Accessed November 22, 2022,
- <https://www.ncbi.nlm.nih.gov/books/NBK546004/>
- 29. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, et al. SOMANZ guidelines for the
- management of hypertensive disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol*. Oct
- 2015;55(5):e1-29. doi:10.1111/ajo.12399
- 30. Magee LA, Smith GN, Bloch C, Cote AM, Jain V, Nerenberg K, et al. Guideline No. 426:
- Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. *J Obstet*
- *Gynaecol Can*. May 2022;44(5):547-571 e1. doi:10.1016/j.jogc.2022.03.002

It is made available under a CC-BY 4.0 International license.

- 31. World Health Organization. *WHO Recommendations for Prevention and Treatment of Pre-*
- *Eclampsia and Eclampsia.* Geneva: World Health Organization; 2011.
- 32. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive
- Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for
- International Practice. *Hypertension*. Jul 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803
- 33. Burchard J, Saade GR, Boggess KA, Markenson GR, Iams JD, Coonrod DV, et al. Better Estimation
- of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating. *J Clin*
- *Med*. May 19 2022;11(10)doi:10.3390/jcm11102885
- 34. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2021.
- *Natl Vital Stat Rep*. Jan 2023;72(1):1-53.
- 35. Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, et al. Screening
- for Preeclampsia: US Preventive Services Task Force Recommendation Statement. *Jama*. Apr 25
- 2017;317(16):1661-1667. doi:10.1001/jama.2017.3439
- 36. Dmitrienko A, Tamhane A, Bretz F, eds. *Multiple Testing Problems in Pharmaceutical Statistics*.

CRC Press; 2009.

- 37. Dmitrienko A, D'Agostino RB, Sr., Huque MF. Key multiplicity issues in clinical drug development.
- *Stat Med*. Mar 30 2013;32(7):1079-111. doi:10.1002/sim.5642
- 38. Burchard J, Polpitiya AD, Fox AC, Randolph TL, Fleischer TC, Dufford MT, et al. Clinical Validation
- of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated
- Clinical Outcomes: A Replication Study. *J Clin Med*. Oct 29 2021;10(21):5088. doi:10.3390/jcm10215088
- 490 39. R Foundation. The R Project for Statistical Computing. Accessed August 1, 2022, [https://www.r-](https://www.r-project.org/)

[project.org/](https://www.r-project.org/)

It is made available under a CC-BY 4.0 International license.

- 40. Yoshida K, Bartel A. tableone: Create 'Table 1' to Describe Baseline Characteristics with or
- without Propensity Score Weights; R package version 0.13.2. Accessed November 21, 2022,
- <https://cran.r-project.org/web/packages/tableone/index.html>
- 41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
- receiver operating characteristic curves: a nonparametric approach. *Biometrics*. Sep 1988;44(3):837-45.
- 42. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with sex
- hormone-binding globulin is stronger than the association with ageing--implications for the
- interpretation of total testosterone measurements. *Clin Endocrinol (Oxf)*. Dec 2015;83(6):828-33.
- doi:10.1111/cen.12768
- 43. Birkebaek NH, Lange A, Holland-Fischer P, Kristensen K, Rittig S, Vilstrup H, et al. Effect of weight
- reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in
- obese children. *Eur J Endocrinol*. Dec 2010;163(6):895-900. doi:10.1530/EJE-10-0538
- 44. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data for 2020. Division
- of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention.
- Updated 2022 Feb 7. Accessed February 9, 2022,<https://www.cdc.gov/nchs/nvss/births.htm>
- 45. March of Dimes Peristats. Births. Accessed July 1, 2023,
- <https://www.marchofdimes.org/peristats/data?reg=99&top=2&stop=10&lev=1&slev=1&obj=3>
- 46. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, et al. Dimeric
- inhibin A as a marker for Down's syndrome in early pregnancy. *N Engl J Med*. May 9 1996;334(19):1231-
- 6. doi:10.1056/NEJM199605093341904
- 47. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as
- possible endocrine markers for pre-eclampsia. *Lancet*. May 3 1997;349(9061):1285-8.
- doi:10.1016/s0140-6736(96)09264-1

It is made available under a CC-BY 4.0 International license.

48. Fraser RF, 2nd, McAsey ME, Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic

pregnancy and correlate with human chorionic gonadotropin. *Am J Reprod Immunol*. Jul 1998;40(1):37-

42. doi:10.1111/j.1600-0897.1998.tb00386.x

49. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin A

and activin A are elevated prior to the onset of pre-eclampsia. *Hum Reprod*. Jul 2000;15(7):1640-5.

doi:10.1093/humrep/15.7.1640

50. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening

with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic

review and meta-analysis. *BMC Pregnancy Childbirth*. Aug 4 2008;8:33. doi:10.1186/1471-2393-8-33

51. Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, Mak-Tam E, et al. Modified multiple

marker aneuploidy screening as a primary screening test for preeclampsia. *BMC Pregnancy Childbirth*.

Mar 8 2022;22(1):190. doi:10.1186/s12884-022-04514-4

52. Goebel EJ, Ongaro L, Kappes EC, Vestal K, Belcheva E, Castonguay R, et al. The orphan ligand,

activin C, signals through activin receptor-like kinase 7. *Elife*. Jun 23 2022;11doi:10.7554/eLife.78197

53. Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, Caniggia I, et al. Nodal signals through activin

receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of

preeclampsia. *Am J Pathol*. Mar 2011;178(3):1177-89. doi:10.1016/j.ajpath.2010.11.066

54. Hu M, Wang Y, Meng Y, Hu J, Qiao J, Zhen J, et al. Hypoxia induced-disruption of lncRNA

TUG1/PRC2 interaction impairs human trophoblast invasion through epigenetically activating

Nodal/ALK7 signalling. *J Cell Mol Med*. Jul 2022;26(14):4087-4100. doi:10.1111/jcmm.17450

55. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. *Biol Reprod*. Sep

2011;85(3):431-41. doi:10.1095/biolreprod.111.092593

It is made available under a CC-BY 4.0 International license.

- 56. Larrea F, Diaz L, Carino C, Larriva-Sahd J, Carrillo L, Orozco H, Ulloa-Aguirre A. Evidence that
- human placenta is a site of sex hormone-binding globulin gene expression. *J Steroid Biochem Mol Biol*.
- Oct 1993;46(4):497-505. doi:10.1016/0960-0760(93)90104-5
- 57. Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG
- regulation and clinical implications. *Trends Endocrinol Metab*. Jul 2015;26(7):376-83.
- doi:10.1016/j.tem.2015.05.001
- 58. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Jr., Bennett
- WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin
- 10 is increased in preeclampsia. *Am J Obstet Gynecol*. Oct 1999;181(4):915-20. doi:10.1016/s0002-
- 9378(99)70325-x
- 59. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with
- preeclampsia. *Am J Reprod Immunol*. Aug 1998;40(2):102-11. doi:10.1111/j.1600-0897.1998.tb00398.x
- 60. Yu CK, Papageorghiou AT, Bindra R, Spencer K, Nicolaides KH. Second-trimester sex hormone-
- binding globulin and subsequent development of pre-eclampsia. *J Matern Fetal Neonatal Med*. Sep
- 2004;16(3):158-62. doi:10.1080/14767050400013297
- 61. Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester
- biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. *Metabolism*.
- Oct 2017;75:6-15. doi:10.1016/j.metabol.2017.07.004

62. Sharifzadeh F, Kashanian M, Fatemi F. A comparison of serum androgens in pre-eclamptic and

- normotensive pregnant women during the third trimester of pregnancy. *Gynecol Endocrinol*. Oct
- 2012;28(10):834-6. doi:10.3109/09513590.2012.683061
- 63. Tuutti EK, Hamalainen EK, Sainio SM, Hiilesmaa VK, Turpeinen UL, Alfthan HV, Stenman UH.
- Serum testosterone levels during early pregnancy in patients developing preeclampsia. *Scand J Clin Lab*
- *Invest*. Sep 2011;71(5):413-8. doi:10.3109/00365513.2011.580858

It is made available under a CC-BY 4.0 International license.

- 64. Sun L, Jin Z, Teng W, Chi X, Zhang Y, Ai W, Wang P. Expression changes of sex hormone binding
- globulin in GDM placental tissues. *J Perinat Med*. Nov 19 2011;40(2):129-35. doi:10.1515/JPM.2011.128
- 65. Anderson DC. Sex-hormone-binding globulin. *Clin Endocrinol (Oxf)*. Jan 1974;3(1):69-96.
- doi:10.1111/j.1365-2265.1974.tb03298.x
- 66. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, et al. Insulin resistance
- and alterations in angiogenesis: additive insults that may lead to preeclampsia. *Hypertension*. May
- 2004;43(5):988-92. doi:10.1161/01.HYP.0000124460.67539.1d
- 67. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin
- resistance. *Clin Endocrinol (Oxf)*. Mar 2013;78(3):321-9. doi:10.1111/cen.12086
- 68. Maggio M, Cattabiani C, Lauretani F, Mantovani M, Butto V, De Vita F, et al. SHBG and
- endothelial function in older subjects. *Int J Cardiol*. Oct 3 2013;168(3):2825-30.
- doi:10.1016/j.ijcard.2013.03.083
- 69. Roberts JM, King TL, Barton JR, Beck S, Bernstein IM, Buck TE, et al. Care plan for individuals at
- risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-
- up. *Am J Obstet Gynecol*. Sep 2023;229(3):193-213. doi:10.1016/j.ajog.2023.04.023
- 70. Clark SL, Saade GA, Tolcher MC, Belfort MA, Rouse DJ, Barton JR, et al. Gestational hypertension
- and "severe" disease: time for a change. *Am J Obstet Gynecol*. May 2023;228(5):547-552.
- doi:10.1016/j.ajog.2022.11.1280

71. Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, et al. RNA profiles

- reveal signatures of future health and disease in pregnancy. *Nature*. Jan 2022;601(7893):422-427.
- doi:10.1038/s41586-021-04249-w
- 72. Rode L, Ekelund CK, Riishede I, Rasmussen S, Lidegaard O, Tabor A. Prediction of preterm pre-
- eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to
- 2017. *Ultrasound Obstet Gynecol*. Oct 2021;58(4):561-567. doi:10.1002/uog.23693

It is made available under a CC-BY 4.0 International license.

- 73. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction.
- *Am J Obstet Gynecol*. Feb 2022;226(2S):S1071-S1097 e2. doi:10.1016/j.ajog.2020.07.020
- 74. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-
- eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. *Ultrasound Obstet Gynecol*.
- Aug 2018;52(2):186-195. doi:10.1002/uog.19112

Table 1. Demographic and clinical characteristics of preterm preeclampsia (PE) cases and noncases in the discovery, verification, and validation

cohorts.

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparisons between cases (PE <37 weeks' gestation) and noncases (no PE or PE ≥37 weeks' gestation) were performed using Wilcoxon or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR²³ and TREETOP²⁴ study protocols. BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

It is made available under a CC-BY 4.0 International license.

Table 2. Predictive performance of ClinRisk3+INHBC/SHBG and a U.S. Preventive Services Task Force

clinical risk factor-based classifier (representing standard care) for risk of preeclampsia with delivery <37

weeks' gestation in the early gestational age dating-restricted population.

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical risk variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; NPV, negative predictive value; LR+/-, positive and negative likelihood ratios; OR, odds ratio; PPV, positive predictive value; SHBG, sex hormone-binding globulin; SPR, screen positive rate; USPSTF, U.S. Preventive Services Task Force.

It is made available under a CC-BY 4.0 International license.

Figure Legends

Fig. 1. Distribution of subjects in the discovery, verification, and validation cohorts.

GA, gestational age.

It is made available under a CC-BY 4.0 International license.

Fig. 2. Receiver operating characteristic performance for the preterm preeclampsia (PE) classifier ClinRisk3+INHBC/SHBG in the full validation cohort. The plots graph sensitivity (true positive rate) vs 1 specificity (false positive rate) for preterm PE cases with gestational age at delivery <37 and <34 weeks among (A) all subjects and (B) nulliparous subjects only.

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; INHBC, inhibin subunit beta c; SHBG, sex hormone binding globulin.

It is made available under a CC-BY 4.0 International license.

Fig. 3. Potential roles of INHBC and SHBG in placentation. (A) Activin C, a homodimer of INHBC, signals through the ALK7 receptor, which is itself dysregulated in preeclampsia. (B) SHBG expression has been demonstrated to be downregulated by pro-inflammatory cytokines in hepatocytes, and its extra-hepatic expression has been shown to include trophoblasts. (C) A model illustrating the association of INHBC, ALK7 and SHBG with abnormal placentation and aberrant spiral artery remodeling.

ActC, activin C, an INHBC homodimer; ACTRII, activin receptor type 2A; ALK7, activin A receptor type 1C; AMPK, AMP-activated protein kinase; c-Jun, Jun proto-oncogene, AP-1 transcription factor subunit; HNF-4α, hepatocyte nuclear factor 4 alpha; IκBα, NFκB inhibitor alpha; IL1β, interleukin 1 beta; IL1β, interleukin 1 beta receptor; INHBC, inhibin subunit beta c; JNK, mitogen-activated protein kinase 8; MEK1/2, mitogen-activated protein kinase kinases 1 and 2; MMP2/9, matrix metalloproteinases 2 and 9; NFκB, nuclear factor kappa B; SHBG, sex hormone binding globulin; SMAD2/3, SMAD family members 2 and 3; TIMP-1, TIMP metallopeptidase inhibitor 1; TNFα, tumor necrosis factor alpha; TNFRα, tumor necrosis factor alpha receptor.

It is made available under a CC-BY 4.0 International license.

Supplemental Digital Content

Appendix 1. Comparison of demographic and clinical characteristics across the discovery, verification,

and validation cohorts.

It is made available under a CC-BY 4.0 International license.

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparison among the three cohorts was performed using Kruskal-Wallis or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR**²³** and TREETOP**²⁴** study protocols.

BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

It is made available under a CC-BY 4.0 International license.

Appendix 2. Validation performance of nine candidate preeclampsia classifier models. Score thresholds are specific to each classifier and differentiate subjects predicted to be at higher risk for preterm preeclampsia, defined as preeclampsia <37 weeks' gestation, from those predicted to be at lower risk. Three score thresholds distinguishing higher from lower risk were validated for each classifier. The linear relationship between the gestational age at delivery and classifier prediction was assessed by the Pearson correlation coefficient. Validation performance is reported across the nine classifiers without protein specific batch calibration.

† Represents CSH1 and CSH2. The two proteins differ by one amino acid residue, which is not included in the peptide fragment measured by the predictor.

AFAM, afamin; AUC, area under the receiver operating characteristic curve; CBPN, carboxypeptidase N catalytic chain; CD14, monocyte differentiation antigen CD14; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; CSH, chorionic somatomammotropin hormone 1/2; IBP4, insulin-like growth factor-binding protein 4; PEDF, pigment epithelium-derived factor; PRG2, bone marrow proteoglycan; SHBG, sex hormone-binding globulin.

It is made available under a CC-BY 4.0 International license.

Appendix 3. Predictive performance of the ClinRisk3+INHBC/SHBG classifier model and a U.S. Preventive

Services Task Force³⁵ clinical risk factor-based classifier (representing standard care) for preterm

preeclampsia risk in the full validation cohort.

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; SHBG, sex hormonebinding globulin.